Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Page 10 of 16
Jun 1, 2026Recent clinical data presented at the American Society of Clinical Oncology highlight linvoseltamab’s high efficacy in inducing complete responses in a majority of patients with light chain amyloidosis, a disease with previously limited treatment options. This article explores the drug’s mechanism, trial outcomes, and broader implications for rare disease therapeutics.
May 31, 2026Cancer immunotherapy has revolutionized oncology care, yet high costs limit access in low-income settings. Recent clinical trial results showcase the promise of ultra-low dose strategies to extend survival in head and neck squamous cell carcinoma, opening new possibilities for global cancer treatment equity.
May 31, 2026Pancreatic cancer is urgently in need of new therapies due to its poor prognosis and resistance to treatment. At ASCO 2026, data emerged from Revolution Medicines demonstrating that daraxonrasib successfully targets a previously 'undruggable' molecule involved in pancreatic cancer progression. These results could herald a new era in managing a notoriously difficult cancer type.
May 29, 2026In a critical advancement for patients suffering from blastic plasmacytoid dendritic cell neoplasm, AbbVie has gained FDA approval for Decnupaz, the first antibody-drug conjugate therapy indicated for this ultra-rare malignancy. This milestone highlights the continuing importance of targeted biopharmaceutical approaches to treat challenging hematologic cancers.
May 25, 2026Eli Lilly has announced promising early results from a clinical trial using its Verve’s gene-editing therapy. The phase 1 study revealed that high-dose treatment significantly reduced cholesterol levels, pointing to new possibilities in gene-based cardiovascular interventions.
May 21, 2026This post dives into the dynamics of Germany's biotech capital, featuring insights from key venture capital experts about the ecosystem's strengths, challenges, and the strategic steps necessary to bolster innovation while maintaining a European base for growth.
May 21, 2026The acquisition of Engage Bio highlights Eli Lilly's continued commitment to genetic medicine innovation by integrating novel delivery technologies aimed at enhancing therapeutic potential and patient outcomes.
May 20, 2026In utero gene therapy represents a novel frontier in genetic disease treatment, aiming to intervene at the earliest possible stage to prevent postnatal disease progression. The upcoming small-scale trial could pave the way for transformative approaches in precision medicine for rare genetic conditions.
May 19, 2026Biotech firms, traditionally motors of scientific discovery and innovation, are increasingly constrained by market pressures stemming from Big Pharma's dominant business models. This growing tension threatens the sector's capacity to innovate. Structural reforms are essential to sustain and nurture biotech’s strategic innovation and maintain its role as a pioneer in biomedical advancements.
May 18, 2026Duracyte's innovative technology leverages engineered cells implanted in patients to produce biologic drugs directly, circumventing traditional manufacturing complexities and enabling real-time control by clinicians. This fusion of biotechnology and electronics heralds a potential shift in drug production and delivery paradigms.
May 14, 2026The FDA has granted approval to BeOne Therapeutics for Beqalzi, its novel therapy for mantle cell lymphoma patients who have experienced relapse or refractory disease. This approval introduces a new class of targeted therapy and represents an important milestone in blood cancer treatment modalities.
May 13, 2026The substantial investment in Isomorphic Labs highlights growing confidence in AI-driven biotechnology research, diverging from traditional investment patterns that favor more developed assets with clinical data.
Machine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.